WuXi Biologics (Cayman) Inc. (WXXWY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY bn | 6 | 10 | 15 | 17 | 19 | 21 | 23 | 27 |
| Operating profit | CNY bn | 6 | 8 | ||||||
| Net profit | CNY bn | 2 | 3 | 4 | 3 | 3 | 5 | 5 | 6 |
| EPS reported | CNY | 2.24 | 2.34 | ||||||
| Operating cashflow per share | CNY | 3.17 | 3.04 | ||||||
| Capex per share | CNY | 1.78 | 1.76 | ||||||
| FCF per share | CNY | 1.39 | 1.28 | ||||||
| Free cash flow | CNY bn | 3 | 4 | ||||||
| Net debt | CNY bn | -15 | -10 | ||||||
| Book value equity | CNY bn | 47 | 48 | ||||||
| Book value per share | CNY | 22.64 | 23.00 | ||||||
| Number of shares | m | 2,087.89 | 2,090.44 | ||||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 24.98 | - | ||||||
| P/B LTM | x | 2.38 | 2.34 | ||||||
| P/S LTM | x | 5.31 | 4.84 | ||||||
| P/FCF LTM | x | 40.31 | 25.48 | ||||||
| EV/EBITDA LTM | x | 13.06 | 11.76 | ||||||
| EV/Sales LTM | x | 5.03 | 6.17 | ||||||
| Earnings Yield LTM | % | +4.00% | +3.43% | ||||||
| FCF Yield | % | +2.48% | +3.93% | ||||||
| Quality | |||||||||
| ROE | % | +10.10% | +10.64% | ||||||
| ROIC | % | +9.01% | +9.26% | ||||||
| Operating margin | % | +30.50% | +30.47% | ||||||
| Gross margin | % | +45.98% | +45.98% | ||||||
| FCF/Sales | % | +13.19% | +12.39% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +43.59% | +50.00% | ||||||
| Sales Growth YoY | % | +13.50% | +24.63% | ||||||
| Net Income Growth YoY | % | +42.27% | +47.03% | ||||||
| FCF Growth | % | +117.05% | +243.41% | ||||||
| Operating Profit Growth | % | +29.99% | +51.53% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.90 | 1.62 | ||||||
| Net Debt/EBITDA | x | -0.75 | -0.77 | ||||||
| EBIT/Net interest | x | 46.46 | 113.46 | ||||||
| Net debt/market cap | % | +0.93% | +0.74% | ||||||
| Net debt/Equity | x | -0.31 | -0.21 | ||||||
| Gross debt/equity | x | 0.07 | 0.06 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided to clients worldwide, with a significant presence in China, North America, and Europe. Beyond its core offerings, the company engages in various specialized activities, including offering expert advice on biopharmaceutical technology, managing international sales agreements, and developing and providing advanced testing solutions. It also handles sales and marketing efforts, supports clinical trials and production of biologics, produces and distributes medical goods, operates a contract development and manufacturing organization (CDMO) for vaccines, and supplies essential materials to the industry. Founded in 2014, WuXi Biologics is based in Wuxi, China, and maintains strategic alliances with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
WuXi Biologics (Cayman) Inc. (WXXWY)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided to clients worldwide, with a significant presence in China, North America, and Europe. Beyond its core offerings, the company engages in various specialized activities, including offering expert advice on biopharmaceutical technology, managing international sales agreements, and developing and providing advanced testing solutions. It also handles sales and marketing efforts, supports clinical trials and production of biologics, produces and distributes medical goods, operates a contract development and manufacturing organization (CDMO) for vaccines, and supplies essential materials to the industry. Founded in 2014, WuXi Biologics is based in Wuxi, China, and maintains strategic alliances with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free